Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition…

Read MoreBio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development
RestorixHealth

Henry Schein Earns Dual Honors at Ragan’s 2023 CSR and Diversity Awards

Henry Schein, Inc. (Nasdaq: HSIC) announced today that Chairman and CEO Stanley M. Bergman was honored as Ragan’s 2023 Executive of the Year for Diversity and Inclusion. The Company also was honored by Ragan Communications, an industry leader in providing professional development, training and…

Read MoreHenry Schein Earns Dual Honors at Ragan’s 2023 CSR and Diversity Awards

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society…

Read MoreMerck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2)…

Read MoreMerck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Viseon Inc. Announces Strategic Market Expansion with 4K Advanced Digital Visualization Enabling Technology

Viseon Inc. announces the company is expanding their addressable market beyond minimally invasive spine surgery to focus on several additional market segments where both open and minimally invasive surgery can benefit clinically as well as economically from the Viseon technology,…

Read MoreViseon Inc. Announces Strategic Market Expansion with 4K Advanced Digital Visualization Enabling Technology

Intellijoint Selects AcuityMD Platform to Accelerate Commercialization of Surgical Navigation Solution

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced that Intellijoint Surgical, developer of surgical planning and navigation solutions for total hip and knee joint replacements, will leverage its platform to identify new business prospects, manage pipeline, and…

Read MoreIntellijoint Selects AcuityMD Platform to Accelerate Commercialization of Surgical Navigation Solution

VUZE Medical to Showcase Next Generation Software-based Guidance System for Spine Surgery at NASS 2023 Following FDA Filing

VUZE Medical, a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has submitted a 510(k) filing with the U.S. Food and Drug Administration (FDA) for VUZE 2.0, its second generation VUZE System. The new, investigational version of…

Read MoreVUZE Medical to Showcase Next Generation Software-based Guidance System for Spine Surgery at NASS 2023 Following FDA Filing

BPGbio to Share Updates in Development of Late-Stage AI-Developed Therapeutic Pipeline at the Pharma Partnering Summit

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming Pharma Partnering Summit in Boston October 19-20, 2023. At the meeting, BPGbio’s President and…

Read MoreBPGbio to Share Updates in Development of Late-Stage AI-Developed Therapeutic Pipeline at the Pharma Partnering Summit

Noom for Work Helps Employers and Payers Provide Clinical Care to Support a Comprehensive Metabolic Health Solution

Noom for Work, Noom’s digital enterprise unit, announced the expansion of its offering to include access to Noom Med, a clinical obesity management solution. With growing employee and member demand for obesity support and anti-obesity medications, the commercial offering for Noom Med…

Read MoreNoom for Work Helps Employers and Payers Provide Clinical Care to Support a Comprehensive Metabolic Health Solution

PFD Week Abstracts Show Leva’s Long-Term Treatment Value for Female Urinary Incontinence Plus New Data for Other Pelvic Floor Disorders

AUGS PFD Week 2023— Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, commends leading researchers in women’s health, who presented data showing that urinary incontinence (UI) symptom relief is durable for two-years following eight-weeks of…

Read MorePFD Week Abstracts Show Leva’s Long-Term Treatment Value for Female Urinary Incontinence Plus New Data for Other Pelvic Floor Disorders